David Kirske - 30 Jun 2026 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Financial Officer
Issuer ticker: XFOR
Reported as of: 30 Jun 2026
Net transaction value: -$36,428
SEC form: 4
Accepted by SEC: 01 Jul 2026, 16:23:25 UTC
Prior SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Mitch Buckley, attorney-in-fact

Key filing fact

David Kirske filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 01 Jul 2026.

Key facts

This page summarizes David Kirske's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 16:23.

Change

Previous filing in this sequence was filed on 13 May 2026.
Current net transaction value: -$36,428.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001276750 Primary reporting owner

KIRSKE DAVID

Relationship: Chief Financial Officer
Address: C/O X4 PHARMACEUTICALS INC., 61 N BEACON STREET, 4TH FLOOR, BOSTON
Signature: /s/ Mitch Buckley, attorney-in-fact
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Sale

Transaction value: $36,428
Shares: -8,543
Change %: -4.8%
Price: $4.26
Shares after: 167,750
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Of the shares of common stock reported, 96,627 shares represent restricted stock units.